We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+43.17%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3.56B
AUM Growth
+$116M
(+3.4%)
Cap. Flow
-$205M
Cap. Flow
% of AUM
-5.76%
Top 10 Holdings %
Top 10 Hldgs %
45.81%
Holding
127
New
13
Increased
20
Reduced
25
Closed
31
Avg Time Held Equity + Options
8.4
quarters
Top 10 Avg Time Held Equity + Options
5.8
quarters
Top 20 Avg Time Held Equity + Options
6.1
quarters
Avg Time Held Equity only
8.6
quarters
Top 10 Avg Time Held Equity only
5.8
quarters
Top 20 Avg Time Held Equity only
6.1
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$79.7M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$45.9M |
| 3 |
Vaxcyte
PCVX
|
+$45.9M |
| 4 |
Madrigal Pharmaceuticals
MDGL
|
+$39.2M |
| 5 |
Acrivon Therapeutics
ACRV
|
+$38.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$158M |
| 2 |
Relmada Therapeutics
RLMD
|
+$88.2M |
| 3 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$43.3M |
| 4 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$38.4M |
| 5 |
Edwards Lifesciences
EW
|
+$27.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.34% |
| 2 | Miscellaneous | 2.57% |
| 3 | Financials | 0.08% |
| 4 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
SLGC
76
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
| $3.77M | 0.11% |
1,500,000
| – | – |
2021 Q3
5 quarters
|
|
77
Tyra Biosciences
TYRA
$1.27B
| $3.76M | 0.11% |
494,403
| – | – |
2021 Q3
5 quarters
|
|
|
PNT
78
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $3.65M | 0.1% |
500,000
| – | – |
2020 Q3
9 quarters
|
|
79
Cypherpunk Technologies Inc
CYPH
$290M
| $3.03M | 0.09% |
672,650
-74,565
| -10% | -$499K |
2020 Q1
11 quarters
|
|
80
Cabaletta Bio
CABA
$268M
| $2.94M | 0.08% |
+317,454
| New | +$1.16M |
2022 Q4
0 quarters
|
|
81
DELISTED
Kronos Bio
KRON
| $2.84M | 0.08% |
1,752,745
-403,406
| -19% | -$929K |
2020 Q4
8 quarters
|
|
82
Procept Biorobotics
PRCT
$1.03B
| $2.68M | 0.08% |
64,537
-199,183
| -76% | -$8.55M |
2021 Q3
5 quarters
|
|
83
Immunovant
IMVT
$5.81B
| $2.66M | 0.07% |
+150,000
| New | +$1.89M |
2022 Q4
0 quarters
|
|
|
ATNX
84
DELISTED
Athenex, Inc. Common Stock
ATNX
| $2.29M | 0.06% |
776,623
| – | – |
2018 Q1
19 quarters
|
|
85
Privia Health
PRVA
$2.78B
| $2.04M | 0.06% |
+90,000
| New | +$2.51M |
2022 Q4
0 quarters
|
|
86
Travere Therapeutics
TVTX
$5.08B
| $1.91M | 0.05% |
90,748
| – | – |
2014 Q1
35 quarters
|
|
87
Acumen Pharmaceuticals
ABOS
$130M
| $1.88M | 0.05% |
347,450
-52,550
| -13% | -$353K |
2022 Q1
3 quarters
|
|
88
DarioHealth
DRIO
$51.5M
| $1.4M | 0.04% |
16,393
| – | – |
2021 Q1
7 quarters
|
|
89
Clover Health Investments
CLOV
$2.55B
| $1.39M | 0.04% |
1,500,000
| – | – |
2021 Q1
7 quarters
|
|
90
DELISTED
NEVRO CORP.
NVRO
| $1.19M | 0.03% |
30,000
-120,000
| -80% | -$4.99M |
2022 Q3
1 quarter
|
|
|
PEAR
91
DELISTED
Pear Therapeutics, Inc. Class A Common Stock
PEAR
| $1.06M | 0.03% |
900,548
| – | – |
2021 Q4
4 quarters
|
|
92
Protara Therapeutics
TARA
$152M
| $777K | 0.02% |
290,051
| – | – |
2020 Q3
9 quarters
|
|
|
MOTS
93
DELISTED
Motus GI Holdings, Inc. Common Stock
MOTS
| $75.6K | ﹤0.01% |
6,002
| – | – |
2018 Q1
19 quarters
|
|
|
EQRXW
94
DELISTED
EQRx, Inc. Warrant
EQRXW
| $67K | ﹤0.01% |
250,000
| – | – |
2021 Q4
4 quarters
|
|
95
DELISTED
CareMax, Inc. Warrant
CMAXW
| $31.3K | ﹤0.01% |
60,000
| – | – |
2021 Q2
6 quarters
|
|
96
DELISTED
Surrozen Inc Warrant
SRZNW
| $9.18K | ﹤0.01% |
166,666
| – | – |
2021 Q3
5 quarters
|
|
97
Absci
ABSI
$1.52B
| – | – |
-894,346
| Closed | -$2.8M | – |
|
98
DELISTED
Apellis Pharmaceuticals
APLS
| – | – |
-366,400
| Closed | -$25M | – |
|
99
C4 Therapeutics
CCCC
$326M
| – | – |
-766,231
| Closed | -$6.72M | – |
|
100
Coherus Oncology
CHRS
$165M
| – | – |
-1,667,123
| Closed | -$16M | – |
|
Similar funds
QP
RWM
AWA
WHRC
KGA
LSERS
CAG
MCM
Perceptive Advisors's Q4 2022 Portfolio in Review
As of Q4 2022, Perceptive Advisors held 127 positions worth $3.56B, up 3.4% from $3.45B the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Perceptive Advisors withdrew a net $205M in Q4 2022, closing 31 positions and reducing 25 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $158M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Perceptive Advisors opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares worth $109M.
- Perceptive Advisors's largest Q4 2022 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 960,000 shares worth $109M.
- Perceptive Advisors added most to Sarepta Therapeutics in Q4 2022, an estimated $45.9M increase.
- Perceptive Advisors's biggest Q4 2022 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $38.4M.
- Perceptive Advisors fully exited Global Blood Therapeutics, Inc. in Q4 2022, selling an estimated $158M.
- Perceptive Advisors's ten largest holdings make up 46% of its $3.56B portfolio in Q4 2022.
- Perceptive Advisors opened 13 new positions and closed 31 in Q4 2022.
- Perceptive Advisors's portfolio value rose 3.4% quarter-over-quarter to $3.56B.
Based on Perceptive Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.